Trial Profile
A Multi-center, Factorial Study to Evaluate Efficacy & Safety of 8 Wks Treatment With VAH631 [Valsartan (40 & 80 mg) and Hydrochlorothiazide (6.25 & 12.5 mg) Combined & Alone in Essential Hypertensive Patients] - Double-blind Study of VAH631 in Patients With Essential Hypertension (Factorial Study)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Feb 2017
Price :
$35
*
At a glance
- Drugs Valsartan/hydrochlorothiazide (Primary) ; Hydrochlorothiazide; Valsartan
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 20 May 2016 New trial record